What did @micaelajaderx actually say?
Nothing about GLP-1 medications. Genuinely nothing. The transcript tagged under the GLP-1 category is a rap or spoken-word audio clip with lyrics referencing money, fans, and self-promotion. There are no medical claims here, no dosing advice, no weight loss tips, and no discussion of semaglutide, tirzepatide, or any related medication. The content is entirely unrelated to the category it was filed under.
The caption reads "Let me put you on this" with a fire emoji, which could theoretically be read as someone about to share a hot tip. But the actual audio that follows is: "Don't you rate up for the month, put the money in my motherfucking hands / I'm a butcher in a bunnist and a motherfucking band." That is not a GLP-1 explainer. That is a rap verse.
Does the science back this up?
There is no scientific claim in this video to evaluate. Since the content contains zero health assertions, there is nothing to verify, debunk, or contextualize against the clinical literature on GLP-1 receptor agonists.
That said, the category mismatch here is worth taking seriously. GLP-1 content on TikTok is a documented mess of misinformation, anecdote, and occasionally accurate information all blended together with no clear labeling. A 2023 analysis published by the Journal of Medical Internet Research found that a significant proportion of weight-loss medication content on short-form video platforms contained either unsupported claims or no clinically actionable information. When videos get miscategorized or mislabeled, they contribute to that noise even when the video itself is harmless. This one is harmless. But the system that tagged it as a GLP-1 video is not doing anyone any favors.
What did they get wrong (or right)?
The creator did not get anything medically wrong because the creator did not make any medical claims. Credit where it is due: this video will not convince anyone to change their semaglutide dose, stack supplements unsafely, or believe their compounded tirzepatide is equivalent to Zepbound. On the narrow question of medical accuracy, it scores perfectly.
What went wrong is the categorization. Whether that is an automated tagging error, a metadata issue, or something else entirely, a video with no GLP-1 content ended up in a GLP-1 fact-check queue. That matters in a regulated telehealth context. Patients searching for credible information about GLP-1 medications deserve content that is actually about those medications. Miscategorized content dilutes the signal and wastes the time of anyone trying to make informed health decisions.
What should you actually know?
If you landed here looking for real information about GLP-1 receptor agonists, here is the short version. Semaglutide and tirzepatide are FDA-approved medications for type 2 diabetes and chronic weight management. They work by mimicking gut hormones that regulate appetite and blood sugar. They are not interchangeable with compounded versions of the same drugs, which are not FDA-approved and may differ in formulation, potency, and sterility standards.
Common side effects include nausea, vomiting, and gastrointestinal discomfort, particularly in the early weeks of treatment. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide produced up to 22.5% body weight reduction in adults with obesity over 72 weeks. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed semaglutide produced approximately 14.9% weight reduction over 68 weeks. These are not miracle cures. They are tools that work best alongside dietary and behavioral support, and they require a prescription from a licensed provider.